GlassScriptPhysician profile
Rajbir Gulati
NPI 1598095226
$3,454.57
in general payments reported to CMS, 2019-2025
27 companies · $550 in 2025
The $550 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,249 · 2020: $295 · 2021: $101 · 2022: $484 · 2023: $384 · 2024: $392 · 2025: $550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,325.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $810.14 | 2019-2025 | |
| Amgen INC. | $500.21 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Horizon Therapeutics Plc | $299.68 | 2019-2023 | Krystexxa |
| Ucb, INC. | $296.76 | 2019-2025 | Bimzelx |
| Pfizer INC. | $198.81 | 2019-2024 | |
| Radius Health, INC. | $195.80 | 2019-2025 | Tymlos |
| Glaxosmithkline, LLC. | $191.79 | 2019-2025 | Benlysta, Nucala |
| Lilly USA, LLC | $183.66 | 2019-2024 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $97.58 | 2019-2025 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.01 | 2019-2023 | Ofev |
| Genzyme Corporation | $84.47 | 2019-2025 | |
| Janssen Biotech, INC. | $79.06 | 2019-2025 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $78.09 | 2023-2024 | Saphnelo, Evusheld |
| Mallinckrodt Hospital Products INC. | $69.51 | 2020 | |
| Genentech USA, INC. | $37.06 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $28.85 | 2025 | Lupkynis |
| Pacira Therapeutics, INC. | $23.82 | 2020 | |
| Janssen Pharmaceuticals, INC | $23.32 | 2020 | |
| Alexion Pharmaceuticals, INC. | $21.82 | 2019 | |
| Abbott Laboratories | $21.49 | 2025 | Eterna |
| Bioventus LLC | $20.43 | 2019 | |
| Organon LLC | $19.74 | 2023 | Hadlima |
| Novartis Pharmaceuticals Corporation | $19.59 | 2025 | |
| Medexus Pharma, INC. | $18.82 | 2019 | |
| Merck Sharp & Dohme LLC | $18.48 | 2019 | |
| Ani Pharmaceuticals, INC. | $14.43 | 2024 | Purified Cortrophin Gel |
| Hikma Pharmaceuticals USA | $13.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajbir Gulati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.